Skip to main content
Erschienen in: World Journal of Urology 1/2024

01.12.2024 | Original Article

The association between patient and disease characteristics, and the risk of disease progression in patients with prostate cancer on active surveillance

verfasst von: Matthijs Duijn, Theo M. de Reijke, Kurdo Barwari, Marias J. Hagens, Sybren P. Rynja, Jos Immerzeel, Jelle O. Barentsz, Auke Jager

Erschienen in: World Journal of Urology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The objective of this study was to identify and assess patient and disease characteristics associated with an increased risk of disease progression in men with prostate cancer on active surveillance.

Methods

We studied patients with low-risk (ISUP GG1) or favorable intermediate-risk (ISUP GG2) PCa. All patients had at least one repeat biopsy. Disease progression was the primary outcome of this study, based on pathological upgrading. Univariate and multivariate Cox proportional hazard analyses were used to evaluate the association between covariates and disease progression.

Results

In total, 240 men were included, of whom 198 (82.5%) were diagnosed with low-risk PCa and 42 (17.5%) with favorable intermediate-risk PCa. Disease progression was observed in 42.9% (103/240) of men. Index lesion > 10 mm (HR = 2.85; 95% CI 1.74–4.68; p < 0.001), MRI (m)T-stage 2b/2c (HR = 2.52; 95% CI 1.16–5.50; p = 0.02), highest PI-RADS score of 5 (HR 3.05; 95% CI 1.48–6.28; p = 0.002) and a higher PSA level (HR 1.06; 95% CI 1.01–1.11; p = 0.014) at baseline were associated with disease progression on univariate analysis. Multivariate analysis showed no significant baseline predictors of disease progression.

Conclusion

In AS patients with low-risk or favorable intermediate-risk PCa, diameter of index lesion, MRI (m)T-stage, height of the PI-RADS score and the PSA level at baseline are significant predictors of disease progression to first repeat biopsy.
Literatur
1.
Zurück zum Zitat Mohler JL, Antonarakis ES, Armstrong AJ et al (2019) Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 17(5):479–505CrossRef Mohler JL, Antonarakis ES, Armstrong AJ et al (2019) Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 17(5):479–505CrossRef
2.
Zurück zum Zitat Kinsella N, Helleman J, Bruinsma S et al (2018) Active surveillance for prostate cancer: A systematic review of contemporary worldwide practices. Transl Androl Urol 7(1):83–97CrossRefPubMedPubMedCentral Kinsella N, Helleman J, Bruinsma S et al (2018) Active surveillance for prostate cancer: A systematic review of contemporary worldwide practices. Transl Androl Urol 7(1):83–97CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Yao SL, Grace LY (2002) Understanding and appreciating overdiagnosis in the PSA era. J Natl Cancer Inst 94(13):958–960CrossRefPubMed Yao SL, Grace LY (2002) Understanding and appreciating overdiagnosis in the PSA era. J Natl Cancer Inst 94(13):958–960CrossRefPubMed
5.
Zurück zum Zitat Wei JT, Dunn RL, Sandler HM et al (2002) Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 20(2):557–566CrossRefPubMed Wei JT, Dunn RL, Sandler HM et al (2002) Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 20(2):557–566CrossRefPubMed
6.
Zurück zum Zitat Al Hussein Al Awamlh B, Patel N, Ma X et al (2021) Variation in the use of active surveillance for low-risk prostate cancer across US census regions. Front Oncol 11:64488CrossRef Al Hussein Al Awamlh B, Patel N, Ma X et al (2021) Variation in the use of active surveillance for low-risk prostate cancer across US census regions. Front Oncol 11:64488CrossRef
7.
Zurück zum Zitat Bokhorst LP, Alberts AR, Rannikko A et al (2015) Compliance rates with the Prostate Cancer Research International Active Surveillance (PRIAS) protocol and disease reclassification in noncompliers. Eur Urol 68(5):814–821CrossRefPubMed Bokhorst LP, Alberts AR, Rannikko A et al (2015) Compliance rates with the Prostate Cancer Research International Active Surveillance (PRIAS) protocol and disease reclassification in noncompliers. Eur Urol 68(5):814–821CrossRefPubMed
8.
Zurück zum Zitat Ploussard G, Epstein JI, Montironi R et al (2011) The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 20(2):291–303CrossRef Ploussard G, Epstein JI, Montironi R et al (2011) The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 20(2):291–303CrossRef
9.
Zurück zum Zitat Cooperberg MR, Carroll PR, Klotz L (2011) Active surveillance for prostate cancer: Progress and promise. J Clin Oncol 29(27):3669–3676CrossRefPubMed Cooperberg MR, Carroll PR, Klotz L (2011) Active surveillance for prostate cancer: Progress and promise. J Clin Oncol 29(27):3669–3676CrossRefPubMed
10.
Zurück zum Zitat Williams C, Khondakar NR, Daneshvar MA et al (2021) The risk of prostate cancer progression in active surveillance patients with bilateral disease detected by combined magnetic resonance imaging-fusion and systematic biopsy. J Urol 206(5):1157–1165CrossRefPubMedPubMedCentral Williams C, Khondakar NR, Daneshvar MA et al (2021) The risk of prostate cancer progression in active surveillance patients with bilateral disease detected by combined magnetic resonance imaging-fusion and systematic biopsy. J Urol 206(5):1157–1165CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Eggener SE, Rumble RB, Armstrong AJ et al (2020) Molecular biomarkers in localized prostate cancer: ASCO guideline. J Clin Oncol 38(13):1474–1494CrossRefPubMed Eggener SE, Rumble RB, Armstrong AJ et al (2020) Molecular biomarkers in localized prostate cancer: ASCO guideline. J Clin Oncol 38(13):1474–1494CrossRefPubMed
13.
Zurück zum Zitat Loeb S, Bruinsma SM, Nicholson J et al (2015) Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. Eur Urol 67(4):619–626CrossRefPubMed Loeb S, Bruinsma SM, Nicholson J et al (2015) Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. Eur Urol 67(4):619–626CrossRefPubMed
14.
Zurück zum Zitat Olivier J, Li W, Nieboer D et al (2022) Prostate cancer patients under active surveillance with a suspicious magnetic resonance imaging finding are at increased risk of needing treatment: results of the movember foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Eur Urol Open Sci 35:59–67CrossRefPubMedPubMedCentral Olivier J, Li W, Nieboer D et al (2022) Prostate cancer patients under active surveillance with a suspicious magnetic resonance imaging finding are at increased risk of needing treatment: results of the movember foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Eur Urol Open Sci 35:59–67CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Iremashvili V, Soloway MS, Rosenberg DL et al (2012) Clinical and demographic characteristics associated with prostate cancer progression in patients on active surveillance. J Urol 187(5):1594–1599CrossRefPubMed Iremashvili V, Soloway MS, Rosenberg DL et al (2012) Clinical and demographic characteristics associated with prostate cancer progression in patients on active surveillance. J Urol 187(5):1594–1599CrossRefPubMed
16.
Zurück zum Zitat Barayan GA, Brimo F, Bégin LR et al (2014) Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort. BJU Int 114(6b):e99–e104CrossRefPubMed Barayan GA, Brimo F, Bégin LR et al (2014) Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort. BJU Int 114(6b):e99–e104CrossRefPubMed
17.
Zurück zum Zitat Iremashvili V, Manoharan M, Rosenberg DL et al (2013) Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models. BJU Int 111(4):574–579CrossRefPubMed Iremashvili V, Manoharan M, Rosenberg DL et al (2013) Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models. BJU Int 111(4):574–579CrossRefPubMed
18.
Zurück zum Zitat Kotb AF, Tanguay S, Luz MA et al (2011) Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance. Prostate Cancer Prostatic Dis 14(1):53–57CrossRefPubMed Kotb AF, Tanguay S, Luz MA et al (2011) Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance. Prostate Cancer Prostatic Dis 14(1):53–57CrossRefPubMed
19.
Zurück zum Zitat Tseng KS, Landis P, Epstein JI et al (2010) Risk stratification of men choosing surveillance for low risk prostate cancer. J Urol 183(5):1779–1785CrossRefPubMedPubMedCentral Tseng KS, Landis P, Epstein JI et al (2010) Risk stratification of men choosing surveillance for low risk prostate cancer. J Urol 183(5):1779–1785CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Bul M, Zhu X, Valdagni R et al (2013) Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 63(4):597–603CrossRefPubMed Bul M, Zhu X, Valdagni R et al (2013) Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 63(4):597–603CrossRefPubMed
Metadaten
Titel
The association between patient and disease characteristics, and the risk of disease progression in patients with prostate cancer on active surveillance
verfasst von
Matthijs Duijn
Theo M. de Reijke
Kurdo Barwari
Marias J. Hagens
Sybren P. Rynja
Jos Immerzeel
Jelle O. Barentsz
Auke Jager
Publikationsdatum
01.12.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 1/2024
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-024-04805-9

Weitere Artikel der Ausgabe 1/2024

World Journal of Urology 1/2024 Zur Ausgabe

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Männern mit Zystitis Schmalband-Antibiotika verordnen

03.05.2024 Zystitis Nachrichten

Die akute Zystitis von Männern und ihre Therapie sind wenig erforscht. Norwegische Forscher haben das nachgeholt. Ihr Rat: Erst einmal keine Breitbandantibiotika verordnen.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.